GSK Exits $4.2bn Cancer Drug Deal With Merck KGaA After Multiple Failures
Plug Pulled After Three Trial Flops
Executive Summary
Bintrafusp alfa was once seen as a blockbuster contender by the partners but GSK’s withdrawal narrows further its chances of success.
You may also be interested in...
Merck KGaA Health Care Head Happy With Old And New Mix
The German firm’s pharma chief Peter Guenter says that while the firm’s lifecycle management of older products is industry-leading, “innovation is the lifeblood of any pharmaceutical company," and he is confident Merck’s promising pipeline will augment its current big earners.
Merck KGaA Healthcare Head Happy With Old And New Mix
The German firm’s pharma chief Peter Guenter tells Scrip that while the firm’s lifecycle management of older products is industry-leading, “innovation is the lifeblood of any pharmaceutical company," and he is confident Merck’s promising pipeline will augment its current big earners.
AstraZeneca Pushes Into GI Cancers With HIMALAYA And TOPAZ-1
Pivotal data presented at the ASCO GI meeting in liver and biliary tract cancers could add a couple of billion dollars to Imfinzi’s sales and breathe new life into the CTL4 inhibitor tremelimumab.